About Amgen (NASDAQ:AMGN)
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:AMGN
- CUSIP: 03116210
- Web: www.amgen.com
- Market Cap: $133.50134 billion
- Outstanding Shares: 729,674,000
- 50 Day Moving Avg: $185.13
- 200 Day Moving Avg: $171.60
- 52 Week Range: $133.64 - $191.10
Sales & Book Value:
- Trailing P/E Ratio: 16.66
- Foreward P/E Ratio: 14.37
- P/E Growth: 3.34
- Annual Revenue: $23.05 billion
- Price / Sales: 5.79
- Book Value: $43.41 per share
- Price / Book: 4.21
- Annual Dividend: $4.60
- Dividend Yield: 2.5%
- EBITDA: $12.36 billion
- Net Margins: 35.46%
- Return on Equity: 29.85%
- Return on Assets: 11.72%
- Debt-to-Equity Ratio: 1.06%
- Current Ratio: 6.20%
- Quick Ratio: 5.82%
- Average Volume: 2.51 million shs.
- Beta: 1.36
- Short Ratio: 2.81
Frequently Asked Questions for Amgen (NASDAQ:AMGN)
What is Amgen's stock symbol?
Amgen trades on the NASDAQ under the ticker symbol "AMGN."
How often does Amgen pay dividends? What is the dividend yield for Amgen?
Amgen announced a quarterly dividend on Friday, July 28th. Shareholders of record on Thursday, August 17th will be given a dividend of $1.15 per share on Friday, September 8th. This represents a $4.60 annualized dividend and a yield of 2.51%. The ex-dividend date of this dividend is Tuesday, August 15th. View Amgen's Dividend History.
How were Amgen's earnings last quarter?
Amgen Inc. (NASDAQ:AMGN) released its quarterly earnings data on Tuesday, July, 25th. The company reported $3.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.84 EPS. View Amgen's Earnings History.
When will Amgen make its next earnings announcement?
What guidance has Amgen issued on next quarter's earnings?
Amgen updated its FY17 earnings guidance on Monday, September, 25th. The company provided earnings per share guidance of $12.15-12.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $12.56. The company issued revenue guidance of $22.5-23.0 billion, compared to the consensus revenue estimate of $22.85 billion.
Where is Amgen's stock going? Where will Amgen's stock price be in 2017?
20 equities research analysts have issued 12-month price targets for Amgen's stock. Their forecasts range from $161.00 to $210.00. On average, they expect Amgen's stock price to reach $191.06 in the next twelve months. View Analyst Ratings for Amgen.
What are analysts saying about Amgen stock?
Here are some recent quotes from research analysts about Amgen stock:
- 1. According to Zacks Investment Research, "Amgen is well positioned for growth with several blockbuster drugs in its portfolio. Amgen’s newer drugs – Prolia, Xgeva, Vectibix, Nplate and Sensipar – are all performing well. Additionally, Amgen’s restructuring plan should make it leaner and more cost efficient. Amgen is also progressing with its pipeline, including biosimilar drugs. Amgen’s shares have outperformed the industry so far this year. However, the company has some challenges in store, given the presence of biosimilar competition and slowdown in sales of mature products. Volume growth of new drugs may not be enough to offset lost sales due to the decline in mature brands. Meanwhile, uptake of Repatha has been slow due to payer restrictions. Estimates have gone up ahead of the company’s Q3 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (10/16/2017)
- 2. Cann analysts commented, "Amgen yesterday announced that the Journal of Clinical Oncology has published positive results from the Imlygic (talimogene laherparepvec) phase II ‘264 study, demonstrating a doubling of response rate or better in the Imlygic combination arm. The data published yesterday in JCO are encouraging, and these along with results from ongoing studies could lead to unexpected adoption of Imlygic and provide upside to our sales estimates. These data demonstrated that Imlygic has a dramatic effect in combination with Yervoy, and the combination looks as strong a much of the reference data for other combinations." (10/6/2017)
- 3. Mizuho analysts commented, "We are increasing our AMGN price target from $183 to $198 on the back of the biotech sector having re-rated somewhat post the GILD/KITE acquisition. We have not changed our estimates." (9/28/2017)
- 4. Cowen and Company analysts commented, "Amgen reported Q1 Revenue of $5.46B (-1% Y/Y, vs. consensus of $5.61BE) and." (4/27/2017)
- 5. BMO Capital Markets analysts commented, "We expect the overall survival (OS) benefit in relapsed myeloma patients to enable Kyprolis to grow in the face of generic competition for Velcade. Upside, however, is in our opinion dependent on data in combination with Revlimid+dex (ECOG Ph3) in newly-diagnosed patients given failure of CLARION. Anecdotal data suggests that Darzalex is best suited in IMiD and proteasome inhibitor failures given lack of response of these agents in patients failing Darzalex." (3/6/2017)
Are investors shorting Amgen?
Amgen saw a increase in short interest in September. As of September 15th, there was short interest totalling 9,412,565 shares, an increase of 29.5% from the August 31st total of 7,267,419 shares. Based on an average daily volume of 3,016,948 shares, the short-interest ratio is currently 3.1 days. Approximately 1.3% of the shares of the company are sold short.
Who are some of Amgen's key competitors?
Some companies that are related to Amgen include Pfizer (PFE), Novartis AG (NVS), Merck & Company (MRK), Novo Nordisk A/S (NVO), Sanofi (SNY), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Celgene Corporation (CELG), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY) and Catalent (CTLT).
Who are Amgen's key executives?
Amgen's management team includes the folowing people:
- Robert A. Bradway, Chairman of the Board, President, Chief Executive Officer
- David W. Meline, Executive Vice President, Chief Financial Officer
- Sean E. Harper, Executive Vice President - Research and Development
- Anthony C. Hooper, Executive Vice President - Global Commercial Operations
- Brian M. McNamee, Executive Vice President - Full Potential Initiatives
- Esteban Santos, Executive Vice President, Operations
- Cynthia M. Patton, Senior Vice President, Chief Compliance Officer
- Jonathan P. Graham, Senior Vice President, General Counsel, Secretary
- Lori A. Johnston, Senior Vice President
- David A. Piacquad, Senior Vice President - Business Development
Who owns Amgen stock?
Amgen's stock is owned by many different of retail and institutional investors. Top institutional investors include APG Asset Management N.V. (0.22%), PGGM Investments (0.10%), State Treasurer State of Michigan (0.03%), Hermes Investment Management Ltd. (0.03%), Oakbrook Investments LLC (0.03%) and Douglas Lane & Associates LLC (0.02%). Company insiders that own Amgen stock include Annette Louise Such, Cynthia M Patton, David Baltimore, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.
Who sold Amgen stock? Who is selling Amgen stock?
Amgen's stock was sold by a variety of institutional investors in the last quarter, including Douglas Lane & Associates LLC, State Treasurer State of Michigan, Bridges Investment Counsel Inc., Oakbrook Investments LLC, Viking Fund Management LLC, Wealth Enhancement Advisory Services LLC, Private Asset Management Inc. and LS Investment Advisors LLC. Company insiders that have sold Amgen stock in the last year include Cynthia M Patton and Sean E Harper. View Insider Buying and Selling for Amgen.
Who bought Amgen stock? Who is buying Amgen stock?
Amgen's stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Hermes Investment Management Ltd., PGGM Investments, APG Asset Management N.V., Meeder Asset Management Inc., Carnick & Kubik Group LLC, Balasa Dinverno & Foltz LLC and Financial Advisory Service Inc.. View Insider Buying and Selling for Amgen.
How do I buy Amgen stock?
Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amgen's stock price today?
MarketBeat Community Rating for Amgen (NASDAQ AMGN)MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Amgen stock can currently be purchased for approximately $182.96.
Consensus Ratings for Amgen (NASDAQ:AMGN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||10 Hold Ratings, 9 Buy Ratings, 1 Strong Buy Rating|
|Consensus Rating:||Buy (Score: 2.55)|
|Consensus Price Target: ||$191.06 (4.42% upside)|Consensus Price Target History for Amgen (NASDAQ:AMGN)
Analysts' Ratings History for Amgen (NASDAQ:AMGN)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/20/2017||BMO Capital Markets||Reiterated Rating||Hold||$198.00||N/A|
|10/13/2017||Barclays PLC||Boost Price Target||Equal Weight||$180.00 -> $190.00||N/A|
|10/6/2017||Oppenheimer Holdings, Inc.||Reiterated Rating||Buy||$203.00||N/A|
|10/6/2017||Morgan Stanley||Reiterated Rating||Overweight||$189.00 -> $196.00||N/A|
|10/5/2017||Bank of America Corporation||Boost Price Target||Buy||$210.00||N/A|
|9/29/2017||Credit Suisse Group||Reiterated Rating||Neutral||$177.00 -> $186.00||Medium|
|9/25/2017||Jefferies Group LLC||Reiterated Rating||Buy||$200.00||Low|
|9/14/2017||Royal Bank Of Canada||Initiated Coverage||Sector Perform -> Sector Perform||$192.00||High|
|7/27/2017||Argus||Boost Price Target||Buy||$180.00 -> $195.00||Low|
|7/26/2017||Deutsche Bank AG||Reiterated Rating||Hold||$172.00 -> $174.00||Low|
|7/22/2017||Cowen and Company||Reiterated Rating||Outperform||$209.00||Low|
|6/26/2017||William Blair||Reiterated Rating||Market Perform||Low|
|6/22/2017||Leerink Swann||Reiterated Rating||Market Perform||$161.00||Low|
|6/8/2017||Sanford C. Bernstein||Set Price Target||Hold||$164.00||Medium|
|4/28/2017||Robert W. Baird||Reiterated Rating||Neutral||$165.00||Low|
|3/20/2017||Goldman Sachs Group, Inc. (The)||Lower Price Target||Conviction-Buy||$208.00 -> $202.00||Low|
|3/14/2017||Piper Jaffray Companies||Reiterated Rating||Overweight||$193.00||Low|
|12/13/2016||Chardan Capital||Upgrade||Sell -> Neutral||N/A|
|9/28/2016||Citigroup Inc.||Lower Price Target||Neutral||$175.00 -> $172.00||N/A|
|9/28/2016||J P Morgan Chase & Co||Reiterated Rating||Hold||N/A|
|2/23/2016||BTIG Research||Reiterated Rating||Sell||$135.00||N/A|
|1/22/2016||Wells Fargo & Company||Reiterated Rating||Hold||N/A|
|12/18/2015||Atlantic Securities||Initiated Coverage||Overweight||$202.00||N/A|
Earnings History for Amgen (NASDAQ:AMGN)Earnings History by Quarter for Amgen (NASDAQ AMGN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/25/2017||Q2 2017||$3.11||$3.27||$5.67 billion||$5.81 billion||View||N/A|
|4/26/2017||Q1 2017||$3.00||$3.15||$5.60 billion||$5.46 billion||View||N/A|
|2/2/2017||Q416||$2.79||$2.89||$5.75 billion||$5.97 billion||View||Listen|
|10/27/2016||Q316||$2.79||$3.02||$5.73 billion||$5.81 billion||View||Listen|
|7/27/2016||Q216||$2.74||$2.84||$5.58 billion||$5.69 billion||View||Listen|
|4/28/2016||Q116||$2.60||$2.90||$5.32 billion||$5.53 billion||View||Listen|
|1/28/2016||Q415||$2.29||$2.61||$5.53 billion||$5.54 billion||View||Listen|
|10/28/2015||Q315||$2.38||$2.72||$5.32 billion||$5.72 billion||View||Listen|
|7/30/2015||Q215||$2.43||$2.57||$5.32 billion||$5.37 billion||View||Listen|
|4/21/2015||Q115||$2.07||$2.48||$4.91 billion||$5.03 billion||View||Listen|
|1/27/2015||Q414||$2.05||$2.16||$5.20 billion||$5.33 billion||View||Listen|
|10/27/2014||Q314||$2.11||$2.30||$4.95 billion||$5.03 billion||View||Listen|
|7/29/2014||Q214||$2.07||$2.37||$4.90 billion||$5.18 billion||View||Listen|
|4/22/2014||Q114||$1.94||$1.87||$4.76 billion||$4.52 billion||View||Listen|
|1/28/2014||Q413||$1.69||$1.82||$4.81 billion||$5.01 billion||View||Listen|
|10/22/2013||Q313||$1.78||$1.94||$4.60 billion||$4.75 billion||View||Listen|
|7/30/2013||Q2 2013||$1.74||$1.89||$4.49 billion||$4.68 billion||View||Listen|
|4/23/2013||Q1 2013||$1.84||$1.96||$4.37 billion||$4.24 billion||View||N/A|
|1/23/2013||Q4 2012||$1.42||$1.40||$4.37 billion||$4.42 billion||View||Listen|
Earnings Estimates for Amgen (NASDAQ:AMGN)
2017 EPS Consensus Estimate: $12.28
2018 EPS Consensus Estimate: $12.67
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Amgen (NASDAQ:AMGN)
|Most Recent Dividend:||9/8/2017|
|Dividend Growth:||28.60% (3 Year Average)|
|Payout Ratio:||41.93% (Trailing 12 Months of Earnings) |
36.77% (Based on This Year's Estimates)
36.14% (Based on Next Year's Estimates)
|Track Record:||6 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Amgen (NASDAQ AMGN)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Amgen (NASDAQ:AMGN)
Insider Ownership Percentage: 0.19%Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Institutional Ownership Percentage: 78.08%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/9/2017||Sean E Harper||EVP||Sell||1,525||$185.95||$283,573.75|| |
|5/24/2017||Cynthia M Patton||SVP||Sell||2,922||$154.40||$451,156.80|| |
|8/2/2016||Annette Louise Such||VP||Sell||3,000||$174.59||$523,770.00|| |
|5/4/2016||Madhavan Balachandran||EVP||Sell||30,000||$154.12||$4,623,600.00|| |
|4/29/2016||David Baltimore||Director||Sell||3,312||$157.21||$520,679.52|| |
|4/29/2016||Sean E Harper||EVP||Sell||21,875||$157.99||$3,456,031.25|| |
|8/31/2015||Carbonnel Francois De||Director||Sell||5,000||$153.84||$769,200.00|| |
|8/19/2015||Fred Hassan||Director||Buy||3,010||$166.63||$501,556.30|| |
|6/2/2015||Cynthia M Patton||SVP||Sell||4,530||$157.06||$711,481.80|| |
|4/23/2015||Stuart A Tross||SVP||Sell||3,012||$169.31||$509,961.72|| |
|4/22/2015||Sean E Harper||EVP||Sell||28,000||$171.58||$4,804,240.00|| |
|3/3/2015||Stuart A Tross||SVP||Sell||4,415||$157.74||$696,422.10|| |
|3/2/2015||David Baltimore||Director||Sell||3,647||$158.76||$578,997.72|| |
|2/11/2015||Robert A Bradway||CEO||Sell||22,000||$152.69||$3,359,180.00|| |
|2/5/2015||Frank C Herringer||Director||Buy||3,000||$152.29||$456,870.00|| |
|12/3/2014||Carbonnel Francois De||Director||Sell||3,000||$168.01||$504,030.00|| |
|8/5/2014||Cynthia M Patton||SVP||Sell||2,644||$127.97||$338,352.68|| |
|8/5/2014||Sean E Harper||EVP||Sell||14,000||$127.29||$1,782,060.00|| |
|5/21/2014||Thomas J.W. Dittrich||CAO||Sell||4,130||$112.83||$465,987.90|| |
|4/28/2014||A Kelly Michael||CFO||Sell||2,065||$110.45||$228,079.25|| |
|3/6/2014||Carbonnel Francois De||Director||Sell||1,000||$126.69||$126,690.00|| |
|9/4/2013||Madhavan Balachandran||EVP||Sell||18,000||$112.76||$2,029,680.00|| |
|8/28/2013||David Baltimore||Director||Sell||4,582||$109.66||$502,462.12|| |
|5/22/2013||Thomas J.W. Dittrich||CAO||Sell||6,130||$104.78||$642,301.40|| |
|5/21/2013||Madhavan Balachandran||EVP||Sell||6,000||$103.28||$619,680.00|| |
|5/17/2013||Rebecca M Henderson||Director||Sell||8,421||$105.72||$890,268.12|| |
|5/16/2013||Cynthia M Patton||SVP||Sell||3,544||$105.01||$372,155.44|| |
|5/14/2013||Judith C Pelham||Director||Sell||25,000||$108.25||$2,706,250.00|| |
Headline Trends for Amgen (NASDAQ:AMGN)
Latest Headlines for Amgen (NASDAQ:AMGN)
Loading headlines, please wait.
Amgen (AMGN) Chart for Sunday, October, 22, 2017